INCA participa de estudo inédito sobre novo fármaco para câncer do colo do útero

Simple item page
dc.TypeArticlept_BR
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva
dc.contributor.authorInstituto Nacional de Câncer (Brasil)
dc.contributor.authorINCA
dc.date.accessioned2022-04-06T14:17:49Z
dc.date.available2022-04-06T14:17:49Z
dc.date.issued2022-03
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/6276
dc.language.isootherpt_BR
dc.publisherINCApt_BR
dc.subjectNeoplasias do Colo do Útero/terapiapt_BR
dc.subjectUterine Cervical Neoplasms/therapypt_BR
dc.subjectNeoplasias del Cuello Uterino/terapiapt_BR
dc.subjectAvaliação de Medicamentospt_BR
dc.subjectDrug Evaluationpt_BR
dc.subjectEvaluación de Medicamentospt_BR
dc.subjectCemiplimabept_BR
dc.subjectMelo, Andréia Cristina dept_BR
dc.titleINCA participa de estudo inédito sobre novo fármaco para câncer do colo do úteropt_BR
dc.title.alternativeInforme INCA 417pt_BR

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Informe-INCA-2022-417-4-INCA-participa-de.pdf
Size:
219.13 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Informe INCA 417